Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/35410
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcGrath, Anne-
dc.contributor.authorAllsep, Helen-
dc.contributor.authorTrajceska, Ljubica-
dc.contributor.authorPham, Tina-
dc.contributor.authorVo, Thu-
dc.date.accessioned2024-07-31T23:02:18Z-
dc.date.available2024-07-31T23:02:18Z-
dc.date.issued2024-07-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/35410-
dc.descriptionResearchFest 2024en_US
dc.description.abstractAim An in-depth review of an error involving the inadvertent administration of a twenty-fold higher dose of metaraminol, due in part to the presence of two metaraminol product concentrations (10 mg/1 mL vials and 3 mg/6 mL vials), recommended keeping a single concentration in operating theatres. Using forcing functions such as removing concentrated solutions associated with risk is a more effective systems-focused intervention when compared with education and training alone.1 To learn from medication incidents for system wide improvement, this study aimed to implement a single concentration of metaraminol throughout the organisation, to reduce the risk of future medication errors. Methods The feasibility of complete removal of the 10 mg/1 mL metaraminol product from Austin Health was tested in partnership with clinicians to ensure viability of a product switch. Alternative products were assessed for quality of packaging and labelling, product availability with secured supply chains, budget impacts and potential wastage. Working closely with the Cerner Electronic Medical Records (EMR) team, the intravenous order sets that display in the EMR were revised. These were crucial to ensure the prescribing and documentation would be clear and unambiguous on changeover day. A one-page summary was published on the hospital intranet, together with signage and focussed communication to medical, nursing and pharmacy staff. Results Prior to changeover day in October 2023, Austin Health had two concentrations of metaraminol in operating theatres, recovery, emergency, intensive care unit and selected procedural areas. The 10 mg/1 mL vials have been removed and replaced with a pre-diluted vial containing 10 mg/ 20 mL. The changes were made in Cerner EMR and infusion orders monitored to ensure a smooth and safe transition. Conclusion Implementation of recommendations from incident reviews may protect consumers and clinicians from administration errors related to wrong product selection. 1. Soong C, Shojania KG. BMJ Qual Saf 2020; 29: 353-357en_US
dc.subjectmedication safetyen_US
dc.subjectforcing functionen_US
dc.subjectrisken_US
dc.subjectmetaraminolen_US
dc.titleForcing functions to reduce risk with metaraminol use at Austin Healthen_US
dc.typeConference Presentationen_US
dc.identifier.affiliationPharmacy Department Austin Healthen_US
dc.identifier.affiliationElectronic Medical Record Services Austin Healthen_US
dc.description.conferencenameResearchFest 2024en_US
dc.description.conferencelocationAustin Healthen_US
dc.type.contentTexten_US
dc.type.contentImageen_US
item.fulltextWith Fulltext-
item.openairetypeConference Presentation-
item.cerifentitytypePublications-
item.grantfulltextopen-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
Appears in Collections:ResearchFest abstracts
Files in This Item:
File Description SizeFormat 
Forcing functions to reduce risk with metaraminol use at AH McGrath A etal 2024.pdfMcGrath A et al, ResearchFest 2024193.95 kBAdobe PDFThumbnail
View/Open
Show simple item record

Page view(s)

166
checked on Feb 21, 2025

Download(s)

28
checked on Feb 21, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.